.png)
.png)
DIRECTOR
Köhler & Milstein Research/Hospital Agustín O’Horán, Mexico
Disclosure(s): AstraZeneca: Board Member, Speaker; Eli Lilly: Board Member; Pfizer: Board Member; Roche: Board Member, Speaker
Dr. Jesús Abraham Simón was born in Dzidzantún (Mayan community), Yucatán, México.
In 1987 he was admitted at the Faculty of Medicine of the Autonomous University of Yucatán where he studied the career of Medical Doctor and was awarded as Medical Internship of the Year. From 1995 he studied the specialty of Internal Medicine and later in 1999 the specialty in Immunology and Rheumatology at the “National Institute of Medical Sciences and Nutrition "Salvador Zubirán", the same Hospital where he did a master's degree in Medical Sciences between 2001 and 2003. He was graduated with honors. In 2003, he studied advanced immunology at the “Swiss Institute for Experimental Cancer Research endorsed by WHO in Geneva Switzerland and did a research fellowship at the “Assistance Hôpitaux publique “Pitié-Salpêtrière”, in Paris France.
Dr Simon has been a member of multiple research societies, such as the Mexican College of Rheumatology and the National System of Researchers. He has been a university professor at various prestigious universities in Mexico, (UNAM, Universidad Autónoma de Yucatán, Anahuac, etc.) in Immunology and Research. As a teacher he has graduated many students.
He has published more than 50 articles in the most impactful journals such as The New England Journal of Medicine, Lancet, Annals of Rheumatic Diseases, etc.
Dr J Abraham, has been the founder of 3 research centers and is currently the C.E.O. of Köhler & Milstein Research. He has received multiple national and international research awards, but the greatest award he has received is the recognition of his patients.
At the beginning of the pandemic, he decided to change his line of research, given the devastating reality of the COVID-19 pandemic and until now he has participated in 20 clinical trials focused in vaccines, monoclonal antibodies, immunoregulators and the development of antivirals against SARS-CoV-2.